Evidence of genetic underexpression in chorionic villi samples of euploid fetuses with increased nuchal translucency at 10–11 weeks' gestation

@article{Farina2006EvidenceOG,
  title={Evidence of genetic underexpression in chorionic villi samples of euploid fetuses with increased nuchal translucency at 10–11 weeks' gestation},
  author={Antonio Farina and Stefano Volinia and Diego Arcelli and Francesca Francioso and Paola Desanctis and Cinzia Zucchini and Gianluigi Pilu and Paolo Carinci and Danila Morano and Maria Carla Pittalis and Patrizio Calderoni and Sonia Vagnoni and Nicola Rizzo},
  journal={Prenatal Diagnosis},
  year={2006},
  volume={26}
}
To retrospectively investigate whether the genetic profile from chorionic villous sampling (CVS) found in euploid fetuses with increased NT differs from matched controls. 
Increased nuchal translucency in euploid fetuses—what should we be telling the parents?
TLDR
Following detection of enlarged NT the majority of babies with normal detailed ultrasound examination and echocardiography will have an uneventful outcome with no increased risk for developmental delay when compared to the general population.
Increased nuchal translucency origins from abnormal lymphatic development and is independent of the presence of a cardiac defect
TLDR
To assess whether cardiac failure, because of cardiac defects, and abnormal jugular lymphatic development are involved in nuchal edema (NE) in various euploid mutant mouse models, morphological equivalent of increased nuchAL translucency is studied.
Identification of circulating placental mRNA in maternal blood of pregnancies affected with fetal congenital heart diseases at the second trimester of pregnancy: implications for early molecular screening
TLDR
To investigate whether a significantly aberrant expression of circulating placental mRNA genes related with cardiogenesis can be detected at the second trimester of pregnancy, a large number of studies have found it to be possible.
Nuchal translucency beyond Down syndrome screening
TLDR
Nuchal translucency (NT) goes far beyond Down syndrome screening, and a detailed first trimester scan is an important step in screening for anomalies and in individual risk assessment.
Maternal plasma mRNA species in fetal heart defects: a potential for molecular screening
TLDR
To verify the hypothesis that aberrant placental mRNA genes related to cardiogenesis can be detected in maternal plasma at the second trimester of pregnancy, a large amount of maternal plasma is tested for these genes in order to establish a baseline for this study.
The anatomy of nuchal translucency at 10–14 weeks gestation in fetuses with Trisomy 21: An incredible medical mystery
TLDR
Further research on the development of the fetal head and neck related to lymphatic development and fluid regulation during 8–14 weeks gestation will enable a greater understanding of how and why increased NT occurs compared to what is currently known.
Ontogeny of Gene Expression: A Changing Environment for Malignancy
TLDR
This poster aims to raise awareness of the importance of routine check-up and informed decision-making in the diagnosis and treatment of children diagnosed with cancer.
A Description of Genetic Counselors' Views and Current Practice with Regard to the Use of Array-CGH for Prenatal Diagnosis
TLDR
With more than half of respondents offering array-CGH for prenatal diagnosis, studies to identify effective counseling strategies are needed.
Fetal cardiac defects and third‐trimester maternal serum placental growth factor
  • A. Curti, C. Zucchini, +5 authors A. Farina
  • Medicine
    Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology
  • 2015
TLDR
The previous data identified dysregulation in the expression pattern of selected genes implicated in the control of heart development and markers of functional abnormalities, such as contractile dysfunction and congestive heart failure, which may result from the presence of CHD, and it is speculated that such genes are somehow associated with the malformed features ofCHD.
Noninvasive prenatal testing for congenital heart disease – cell-free nucleic acid and protein biomarkers in maternal blood
  • Orsolya Bíró, J. Rigo, B. Nagy
  • Medicine
    The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians
  • 2018
TLDR
Specific cell-free RNAs and circulating proteins seem to be potential biomarkers for fetal CHDs, and the application of these new biomarkers could improve the detection rate at early pregnancy, making it possible to provide optimal perinatal and perioperative management.
...
1
2
...

References

SHOWING 1-10 OF 26 REFERENCES
Changes in nuchal translucency thickness in normal and abnormal karyotype fetuses
TLDR
The dynamic trend of the nuchal translucency thickness between fetuses with normal and abnormal karyotype is investigated to find out if there is a relationship between maternal age, sex, and karyotypes.
Disappearance of enlarged nuchal translucency before 14 weeks' gestation: relationship with chromosomal abnormalities and pregnancy outcome
The aim of this study was to investigate the natural course of enlarged nuchal translucency (NT) and to determine if its disappearance before 14 weeks' gestation is a favorable prognostic sign in
First trimester fetal nuchal translucency: Problems with screening the general population 2.
TLDR
First trimester nuchal translucency 3 mm as a screening test for aneuploidy in the normal pregnant population is investigated.
Trisomy 10: first‐trimester features on ultrasound, fetoscopy and postmortem of a case associated with increased nuchal translucency
TLDR
Postmortem examination confirmed major anatomical malformations, including facial cleft, arthrogryposis of the upper and lower limbs and bilateral diaphragmatic hernia, and also revealed hypoplastic lungs, right renal agenesis and a complex cardiac malformation.
Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities.
  • K. Nicolaides
  • Medicine
    American journal of obstetrics and gynecology
  • 2004
TLDR
There is extensive evidence that effective screening for major chromosomal abnormalities can be provided in the first trimester of pregnancy, and care givers who perform first-trimester screening should be trained appropriately, and their results should be subjected to external quality assurance.
Lymphatic malformation in human fetuses
  • S. Putte
  • Biology, Medicine
    Virchows Archiv A
  • 2004
TLDR
In 7 spontaneously aborted fetuses characterized by a large cystic hygroma in the nuchal region and a prominent and generalized edema, the structure and extension of the lymphatic system was studied and it is suggested that the disorder is essentially a generalized hypoplasia and partial agenesis of theymphatic system, which ceases to extend peripherally at an early embryonic stage.
Morphological classification of nuchal skin in human fetuses with trisomy 21, 18, and 13 at 12—18 weeks and in a trisomy 16 mouse
TLDR
The skin edema in Fetal trisomies is characterized by specific alterations of the extracellular matrix that may be attributed to gene dosage effects as a result of a genetic imbalance due to the condition of fetal trisomy.
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
TLDR
Western and immunohistochemical analysis revealed that absence of a second X chromosome, as is the case in Turner syndrome, affects BGN protein pattern, and an abnormal amount of glycosaminoglycans and proteoglyCans presumably contributes to increased nuchal translucency.
Hyaluronan in the nuchal skin of chromosomally abnormal fetuses.
TLDR
The finding suggests that hyaluronan may be implicated in the pathogenesis of increased NT in fetuses with trisomy 21, but the common phenotypic expression of increased translucency in different chromosomal abnormalities may be the consequence of other mechanisms.
First-trimester nuchal translucency and cardiac septal defects in fetuses with trisomy 21.
TLDR
The incidence of ventricular and atrioventricular septal defects is much higher in fetuses with trisomy 21 and increased nuchal translucency thickness at 10 to 13 weeks' gestation than in live-born infants with this chromosomal abnormality.
...
1
2
3
...